Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Transplantation Using Hepatitis C Positive Donors, A Safety Trial

also receive ezetimibe, a cholesterol-lowering medication that also blocks entry of HCV into liver cells. They will then receive daily dosing of the same medications for 7 days after transplant. The

glecaprevir
pibrentasvir
antiviral drugs
  • 10 views
  • 12 Feb, 2022
  • 1 location
Role of A2A Receptor in Hypercholesterolemic Patients

(statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better

hypercholesterolemia
pcsk9
hmg-coa reductase inhibitors
atherosclerosis
cardiovascular disease
  • 0 views
  • 15 Nov, 2021
  • 1 location
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases

(10 -20%).Till date, there is no US-FDA approved therapy for NAFLD but drugs like metformin, pioglitazone, sitagliptin, vildagliptin Vitamin E, silymarin, statins and ezetimibe have been studied along

  • 0 views
  • 19 Jul, 2021
  • 1 location
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI (CONTRAST-2)

addition to the standard therapy. If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10

  • 0 views
  • 23 May, 2022
  • 1 location
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient …

  • 0 views
  • 29 Oct, 2021
  • 1 location
Influence of Lipid Lowering on Impaired Coronary Flow

This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow

  • 0 views
  • 24 May, 2022
  • 1 location
Effect of PCSK9 InhibitorS On Calcific Aortic Valve DiseasE

Calcific Aortic Stenosis (CAS) can cause severe adverse cardiac events, but there is currently no effective drug that can prevent or delay the progression of the disease, aortic valve replacement is still the only therapy. The epidemiology of CAS shows that it is related with level of Lp(a)LDL-C and PCSK9. …

stenosis
aortic valve stenosis
  • 0 views
  • 17 Sep, 2021
  • 1 location
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

This study is designed to evaluate the efficacy of automated electronic alerts in the electronic health record to improve rates of best practices in the treatment of patients with hyperlipidemia who present in the setting of outpatient primary care and family medicine practices within the Yale New Haven Health System.

  • 0 views
  • 24 May, 2022
  • 4 locations
Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

IBI306 is a bio-innovative drug against proprotein convertase subtilisin 9 (PCSK-9) monoclonal antibody. Currently, cholesterol-lowering drugs with multiple mechanisms of action are on the market or under development. Among them, anti-PCSK-9 monoclonal antibodies have received widespread attention due to their good safety and efficacy. The results of existing preclinical studies …

  • 0 views
  • 10 Jul, 2021
  • 1 location
Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 (CONTRAST-3)

It is planned to include 200 patients hospitalized with primary myocardial infarction with and without ST segment elevation (STEMI or NSTEMI) in combination with COVID-19 within the first 15 days from the disease onset. The total follow-up period is 96 weeks. Hypotheses An integrated approach in assessing myocardial contractility, regulation …

atorvastatin
cardiac death
q waves
angiography
atherosclerosis
  • 0 views
  • 27 May, 2022
  • 1 location